Atrial fibrillation resident survival guide: Difference between revisions
Jump to navigation
Jump to search
Line 34: | Line 34: | ||
== Management== | == Management== | ||
Pharmacological management of patients of with newly discovered atrial fibrillation | Pharmacological management of patients of with newly discovered atrial fibrillation:<ref name="Fuster-2011">{{Cite journal | last1 = Fuster | first1 = V. | last2 = Rydén | first2 = LE. | last3 = Cannom | first3 = DS. | last4 = Crijns | first4 = HJ. | last5 = Curtis | first5 = AB. | last6 = Ellenbogen | first6 = KA. | last7 = Halperin | first7 = JL. | last8 = Kay | first8 = GN. | last9 = Le Huezey | first9 = JY. | title = 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. | journal = Circulation | volume = 123 | issue = 10 | pages = e269-367 | month = Mar | year = 2011 | doi = 10.1161/CIR.0b013e318214876d | PMID = 21382897 }}</ref> | ||
{{familytree/start |summary=PE diagnosis Algorithm.}} | {{familytree/start |summary=PE diagnosis Algorithm.}} | ||
Line 52: | Line 52: | ||
Pharmacological management of patients of with recurrent paroxysmal atrial fibrillation | Pharmacological management of patients of with recurrent paroxysmal atrial fibrillation:<ref name="Fuster-2011">{{Cite journal | last1 = Fuster | first1 = V. | last2 = Rydén | first2 = LE. | last3 = Cannom | first3 = DS. | last4 = Crijns | first4 = HJ. | last5 = Curtis | first5 = AB. | last6 = Ellenbogen | first6 = KA. | last7 = Halperin | first7 = JL. | last8 = Kay | first8 = GN. | last9 = Le Huezey | first9 = JY. | title = 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. | journal = Circulation | volume = 123 | issue = 10 | pages = e269-367 | month = Mar | year = 2011 | doi = 10.1161/CIR.0b013e318214876d | PMID = 21382897 }}</ref> | ||
{{familytree/start |summary=PE diagnosis Algorithm.}} | {{familytree/start |summary=PE diagnosis Algorithm.}} |
Revision as of 14:32, 12 August 2013
Conduction | ||
Sinus rhythm | Atrial fibrillation |
Atrial Fibrillation Microchapters | |
Special Groups | |
---|---|
Diagnosis | |
Treatment | |
Cardioversion | |
Anticoagulation | |
Surgery | |
Case Studies | |
Atrial fibrillation resident survival guide On the Web | |
Directions to Hospitals Treating Atrial fibrillation resident survival guide | |
Risk calculators and risk factors for Atrial fibrillation resident survival guide | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Definition
Atrial fibrillation (AF or Afib) is a cardiac arrhythmia (abnormal heart rhythm) that involves the two upper chambers (atria) of the heart.
Causes
Life Threatening Causes
Common Causes
- COPD
- Coronary heart disease
- Drugs
- Hypertension
- Hypertensive heart disease
- MI
- Rheumatic heart disease
- Sick sinus syndrome
- Sleep apnea
- Stress
- Thyrotoxicosis
- Valvular heart disease
Management
Pharmacological management of patients of with newly discovered atrial fibrillation:[1]
Newly discovered AF | |||||||||||||||||||||||||||||||||||||
Paroxysmal | Persistent | ||||||||||||||||||||||||||||||||||||
No therapy needed unless severe symptoms (e.g., hypotension, HF, angina pectoris | Accept permanent AF | Rate control and anticoagulation as needed | |||||||||||||||||||||||||||||||||||
Anticoagulation as needed | Anticoagulaion and rate control as needed | Consider antiarrhythmic drug therapy | |||||||||||||||||||||||||||||||||||
Cardioversion | |||||||||||||||||||||||||||||||||||||
Long term antiarrhythmic drug therapy unnecessary | |||||||||||||||||||||||||||||||||||||
Pharmacological management of patients of with recurrent paroxysmal atrial fibrillation:[1]
Recurrent paroxysmal AF | |||||||||||||||||||||||||||||||||
Minimal or no symptoms | Disabling symptoms in AF | ||||||||||||||||||||||||||||||||
Anticoagulation and rate control as needed | Anticoagulation and rate control as needed | ||||||||||||||||||||||||||||||||
No drug for prevention of AF | Antiarrhythmic drug therapy | ||||||||||||||||||||||||||||||||
AF ablation if ADD treatment fails | |||||||||||||||||||||||||||||||||
ADD indicates antiarrhythmic drugs
References
- ↑ 1.0 1.1 Fuster, V.; Rydén, LE.; Cannom, DS.; Crijns, HJ.; Curtis, AB.; Ellenbogen, KA.; Halperin, JL.; Kay, GN.; Le Huezey, JY. (2011). "2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines". Circulation. 123 (10): e269–367. doi:10.1161/CIR.0b013e318214876d. PMID 21382897. Unknown parameter
|month=
ignored (help)